Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Takeda Pharmaceutical Co announces termination of Orteronel (TAK-700) development for prostate cancer in Japan, U.S.A. and Europe


Thursday, 19 Jun 2014 02:00am EDT 

Takeda Pharmaceutical Co Ltd:Voluntarily decided to end the development program for orteronel (TAK-700) for prostate cancer.Decision follows the results of two Phase 3 clinical trials in metastatic, castration resistant prostate cancer.Studies found while orteronel plus prednisone could extend the time patients lived before their cancer progressed, it did not extend overall survival in these patients.Says the drug has not demonstrated a clinical profile sufficient to move forward in mCRPC, given the availability of other therapies.